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Clinical Markers of Crohn’s Disease Severity and Their 
Association With Opiate Use
Mary Cheunga, Sundas Khanb, Meredith Akermanc, Chun Kit Hungb, Kaitlyn Vennardb, Nicholas Hristisb, 
Keith Sultana, d
Abstract
Background: The safety of opiate use for patients with Crohn’s dis-
ease (CD) has long been a concern. The recent Crohn’s therapy, re-
source, evaluation, and assessment tool (TREAT) registry update has 
added to these concerns by demonstrating an association of opiate use 
with an increased risk of infection and death in CD. While the asso-
ciation is clear, the relationship of opiates to these negative outcomes 
is not. It is unknown whether opiates are a contributing factor to these 
negative outcomes or if their use is merely a marker of more severe 
disease. We hypothesized that opiate use is not harmful in CD but is 
a marker of disease severity and would be associated with commonly 
accepted clinical markers of severe CD such as early age at CD onset, 
disease duration, small intestinal involvement, a history of fistula or 
stricture, and lower quality of life (QOL) scores.
Methods: Data on CD history including pain medication usage were 
obtained from an interviewer directed survey of patients admitted to 
two tertiary care hospitals over a 2-year period. CD as the primary 
admitting diagnosis was not required. Active opiate use was defined 
by usage within the past month prior to admission.
Results: A total of 133 patients were approached to participate, of 
whom 108 consented to the survey, and 51 were active opiate users. 
Opiate using CD patients were more commonly smokers (22% vs. 
3.45%, P < 0.010), had fistulas (40% vs. 22.4%, P < 0.048) and had a 
poorer quality of life score by short form inflammatory bowel disease 
questionnaire (mean 3.80 vs. 4.34, P < 0.036) than non-opiate users. 
No difference was found between opiate users and non-users for age 
of diagnosis, disease duration, or a history of strictures.
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Conclusions: The study findings demonstrate that opiate use in CD is 
associated with markers of disease severity including fistulas, smok-
ing, and lower QOL scores. The findings suggest that opiates may not 
be directly harmful to patients with CD, but may merely be another 
marker of disease severity. However, given opiates unproven benefits 
for long term CD pain control and risk of dependence, caution should 
still be exercised in their use.
Keywords: Crohn’s disease; Opiates; Fistulas; Smoking; Inflamma-
tory bowel disease
Introduction
Effective and safe pain management for patients with Crohn’s 
disease (CD) has long been a source of controversy. Non-steroi-
dal anti-inflammatory medications (NSAIDs) may pose a risk 
of CD exacerbation [1], and though opiate pain medications 
may be effective for acute pain, their usefulness for chronic 
CD related pain is unproven. Additionally, opiates pose a risk 
of addiction [2] and in the case of chronic abdominal pain may 
even cause a paradoxical worsening of pain symptoms termed 
narcotic bowel syndrome [3]. There are also concerns that opi-
ates may mask CD complaints, thus altering management and 
outcomes [4]. Recent data from the Crohn’s therapy, resource, 
evaluation, and assessment tool (TREAT) registry update have 
added to these concerns by noting an association between opi-
ate use and the development of infections and an increased risk 
of death [5].
Prior studies have examined factors associated with opiate 
use in CD. Cross et al reviewed 291 CD patients over a 5-year 
period, of which 38 were chronic opiate users [6]. The authors 
found opiate use to be associated with disease activity, disabil-
ity, female gender, polypharmacy, smoking, and longer disease 
durations. In another analysis, Hanson et al matched 100 opi-
ate using mixed inflammatory bowel disease (IBD) patients 
with 100 non-opiate using controls [7]. An association was 
found with female gender, moderate to severe pain, depres-
sion, anxiety, history of abuse (sexual, emotional, or physical) 
and for substance abuse apart from alcohol. Earlier work by 
Edwards et al also noted a strong association between opiate 
use and psychiatric disorders [8].
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While each of these studies provides important insights 
into associated co-factors possibly contributing to opiate use, 
the question remains: are opiates a marker of disease severity 
and the associated negative outcomes, or a cause of these nega-
tive outcomes? Both Cross and Hanson found a relationship 
between opiate use and smoking, which is known to be associ-
ated with worsened disease severity and poorer outcomes [9]. 
Other clinical factors commonly associated with severe CD 
include early age at CD onset, disease duration, small intes-
tinal involvement, and a history of fistula or stricture [10-14] 
and quality of life (QOL) scores. We hypothesized that opiates 
are not harmful to patients with CD, but rather are a marker of 
more severe CD and would be associated with these clinical 
factors.
Materials and Methods
Data were obtained from an interviewer directed survey of CD 
patients upon admission to two acute care, non-referral center 
hospitals over a 2-year period. Patients were identified by an 
electronic medical record search of admission history docu-
ments for the keyword “Crohn’s” or “Crohn”. Following iden-
tification as a potential study candidate, patients themselves 
needed to confirm a diagnosis of CD. CD exacerbation as the 
primary admitting diagnosis was not required. CD history ob-
tained included age of diagnosis, disease duration, disease lo-
cation, history of fistula, history of stricture, smoking status, 
opiate use, and QOL with the short form inflammatory bowel 
disease questionnaire (SIBDQ). Pain assessment was obtained 
using the Harvey Bradshaw index (HBI) pain subscore ques-
tion 2 (HBI Q2) along with SIBDQ pain subscore question 4 
(SIBDQ Q4). Irritable bowel syndrome (IBS) was diagnosed 
by ROME III criteria. Current opiate use was defined as usage 
within the month prior to hospital admission. The survey was 
comprised of closed ended questions administered at the bed-
side by either the division research coordinator or a research 
volunteer trained by the coordinator. The study including the 
survey was approved by our institutional review board.
Statistical methods
Current opiate users and non-opiate users were compared us-
ing the Chi-square test or Fisher’s exact test, as deemed ap-
propriate, for categorical variables and the two-sample t-test 
was used to compare the two groups for continuous variables. 
Disease duration was analyzed by applying standard methods 
of survival analysis, i.e., computing the Kaplan-Meier product 
limit curves, where group (opiate user vs. non-opiate user) was 
the stratification variable. No data were considered censored. 
The two groups were compared using the log-rank test. The 
median disease duration and corresponding 95% confidence 
intervals for each group were obtained from the Kaplan-Meier/
product-limit estimates.
A result was considered statistically significant at the P < 
0.05 level of significance. All analyses were performed using 
SAS version 9.3 (SAS Institute Inc., Cary, NC, USA).
Results
One hundred thirty-three CD patients were approached with 
108 patients consenting to the questionnaire. Sixty-seven pa-
tients (62%) were male and 51 (47%) were current opiate users. 
All opiate use was for pain control, i.e. none for management 
of diarrhea. There was no significant difference between opiate 
users and non-users for any demographic variable (Table 1).
Current tobacco use was more common among current 
opiate users vs. non-opiate users (22% vs. 3.45%, P < 0.010) 
(Table 2). A history of fistula was more common in opiate vs. 
non-opiate users (40% vs. 22.4%, P < 0.048). Enteroenteric 
fistulas were the only fistula subtype associated with opiate 
use (22% vs. 6.9%, P < 0.024). A univariate logistic regression 
model was run for the entire group of 108 patients to examine 
for any relationship between smoking status and fistulas. There 
was no evidence of active smoking status predicting fistulas (P 
< 0.6948). A univariate logistic regression model was also per-
formed for the 51 current opiate users. Again, there was no evi-
dence of active smoking status predicting fistulas (P < 0.9154).
Strictures (76% vs. 68.97%, P < 0.416) and small bowel 
disease (40% vs. 31%, P < 0.331) were not associated with 
opiate use. There was a non-significant trend towards a history 
of bowel resection among the opiate using patients (54% vs. 
36.2%, P < 0.064). There was no difference between opiate 
users vs. non-opiate users for age of diagnosis (29.4 vs. 33.4 
years, P < 0.213) or disease duration (median 14.5 years vs. 
15.0 years, P < 0.769). Opiate use was not found to be associ-
ated with alcohol, cocaine, or marijuana use. Abdominal pain 
by HBI Q2 score was similar between opiate and non-opiate 
users (mean 2.11 vs. 1.82, P < 0.243) as was abdominal pain 
by IBDQ Q4 score (mean 3.67 vs. 4.13, P = 0.297), although 
QOL was significantly lower (mean 3.80 vs. 4.34, P < 0.036) 
for opiate users.
Table 1.  Patient Demographics
Opiate users (n = 50) Non-opiate users (n = 58) P-value
Age 48.46 ± 15.99 52.28 ± 18.96 0.265
Gender (males) 30 (60.00%) 37 (63.79%) 0.686
Age of diagnosis 29.41 ± 15.68 33.42 ± 16.78 0.213
Disease duration (years) 14.5 (12.0, 24.0) 15.0 (10.0, 21.0) 0.769
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Discussion
In this non-referral center based study of hospitalized patients 
with CD, we have confirmed prior reports showing an associa-
tion between opiate use and active smoking [6, 7], and have 
observed a novel association of opiates with a history of fistu-
las. Though it has been suggested that smoking itself might be 
associated with fistulas in CD [15], there are little data to sup-
port this, and our univariate logistic regression analysis shows 
no evidence that this was the case for our patients specifically. 
Fistulas are among the most objective findings of severe CD. 
While opiates may mask or even mimic symptoms of CD, there 
is no known mechanism by which they cause fistulas, sug-
gesting opiates as a response to disease severity in our patient 
population rather than a cause of disease severity. Additionally 
we noted that QOL was lower among opiate users. While QOL 
determined by questionnaire is not as objective a finding as 
fistula, it too correlates with disease severity and suggests an 
increased disease burden in the opiate users [16, 17].
The main limitation of our study, common to any survey 
based investigation, is the dependence upon patient recall. 
While “objective” disease findings for details such as age of 
diagnosis are less likely to be affected by the survey format, 
it would be reasonable to question the accuracy of patient re-
call of details such as disease location and history of fistula or 
stricture without imaging, endoscopic or surgical reports for 
confirmation. Though the patients were seen in a tertiary care 
setting, the hospitals involved are not part of a closed system. 
As such, the vast majority of patients interviewed were fol-
lowed by community gastroenterologists, with their outpatient 
records such as endoscopic reports and imaging inaccessible 
to review by the study team. Although our survey was not 
validated against patient medical records, recent experience 
with patient self reporting of IBD survey data as part of the 
Crohn’s and Colitis Foundation Partners (CCFA) study has in 
fact shown a good correlation between patient knowledge and 
disease history [18].
Other potential limitations of the study include the method 
and location of recruitment. Identification of study candidates 
required documentation of CD within the admission history 
of the hospitals’ electronic medical record. Particularly for pa-
tients admitted without active CD related complaints, it is like-
ly that some patients did not have their CD history documented 
Table 2.  Clinical Characteristics and History
Opiate users (n = 50) Non-opiate users (n = 58) P-value
SIBDQ 3.80 ± 1.21 4.34 ± 1.35 0.036
IBS diagnosis 10 (20.00%) 8 (13.79%) 0.388
History of fistula 20 (40.00%) 13 (22.41%) 0.048
  Enterocutaneous 4 (8.00%) 4 (6.90%) 1.000
  Enteroenteric 11 (22.00%) 4 (6.90%) 0.024
  Entervesicular 1 (2.00%) 0 (0.00%) 0.463
  Rectovaginal 1 (2.00%) 3 (5.17%) 0.622
  Perianal 9 (18.00%) 12 (20.69%) 0.725
Any surgical history 33 (66.00%) 36 (62.07%) 0.672
History of abscess drain 12 (24.00%) 15 (25.86%) 0.824
History of bowel resection 27 (54.00%) 21 (36.21%) 0.064
Ostomy 9 (18.00%) 12 (20.69%) 0.725
Stricture 8 (16.00%) 10 (17.24%) 0.863
Tobacco
  Current 11 (22.00%) 2 (3.45%) 0.010
  Past 18 (36.00%) 22 (37.93%)
  Never 21(42.00%) 34 (58.62%)
Past cocaine 1 (2.00%) 1 (1.72%) 1.000
Past marijuana 6 (12.00%) 7 (12.07%) 0.991
Alcohol
  Daily 3 (5.26%) 2 (4.00%) 0.479
  Weekly 10 (17.54%) 8 (16.00%)
  Monthly 10 (17.54%) 9 (18.00%)
  Few times/year 24 (42.11%) 15 (30.00%)
  Never 10 (17.54%) 16 (32.00%)
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and were thus missed. Also, while our study benefits from the 
non-referral based setting of patient recruitment, the inpatient 
location of patient recruitment might bias towards individuals 
with more severe disease overall. While this had the benefit of 
providing a population of CD patients with higher rates of opi-
ate use to analyze than seen by prior investigators, it is possible 
that this may not reflect the broader CD population.
In conclusion, we report the new finding of an associa-
tion between opiate use and a history of fistula among patients 
with CD. We also provide further evidence of an association 
between smoking and opiate use in this population as well as 
poorer QOL scores among opiate users. Both fistula and smok-
ing have been previously associated with more severe CD, 
suggesting that the use of opiates in this population may be 
a response to disease severity rather than a cause of disease 
severity. Even if we accept the conclusion that opiates are not 
directly harmful to patients with CD, this should not be viewed 
as an immediate license for increased usage. The risk of addic-
tion or dependence as well as the unproven benefits of opiates 
for long term control of CD pain should be enough to recom-
mend for continued caution with their use.
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